Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib treatment optimization in ≥ 3rd line CML-CP
2024-511381-36-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label trial of asciminib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Major molecular response (MMR) at 48 weeks. Started Jun 2024; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on 2024-511381-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511381-36-00.